CStone Pharmaceuticals (2616.HK)

0.900 0.000 (0.00%) At close: 04:08PM HKT

CStone Pharmaceuticals

C1 Building
218 Xinghu Street North Block Suzhou Industrial Park
Suzhou 215123
China
86 512 8718 6550
https://www.cstonepharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 474

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Jianxin Yang M.D., Ph.D.	CEO and President of R&D	2.75M	N/A	1964
Ms. Weicong Ni	Chief Financial Officer	N/A	N/A	N/A
Dr. Ngai Chiu Tse M.D., Ph.D.	Senior VP & Chief Scientific Officer	N/A	N/A	1968
Mr. Michael J. Choi M.B.A.	Chief Commercial Officer & Chief Strategy Officer	N/A	N/A	1975
Man Liu	Head of Commercial	N/A	N/A	N/A
Ms. Yin Kwan Ho	Joint Company Secretary	N/A	N/A	1977

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.

Description

CStone Pharmaceuticals, a biopharmaceutical company, researches, develops, and commercializes immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and internationally. It offers Sugemalimab, a monoclonal antibody against programmed death (PD) ligand 1; GAVRETO, an RET inhibitor for the treatment of patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers; and avapritinib, a KIT/PDGFRA inhibitor to treat adults with unresectable or metastatic gastrointestinal stromal tumors harboring a PDGFRA exon 18 mutation. The company's product pipeline includes Nofazinlimab, a PD-1 antibody for the treatment of patients with hepatocellular carcinoma; and Ivosidenib, an isocitrate dehydrogenase 1 (IDH1) inhibitor to treat adults with relapsed or refractory acute myeloid leukemia with an IDH1 mutation. Its products also comprise CS1002, CS2006, CS3005, CS2007, CS2008, CS6001, and CS500 for solid tumors; and CS5001 for solid tumors and hematologic malignancies. The company was incorporated in 2015 and is headquartered in Suzhou, China.

Corporate governance

CStone Pharmaceuticals’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.